Subscribe to Press Releases

X
Subscribe

Immunotherapies for Life

YmAbs Announces Closing of $30 Million Extension of Private Equity Placement

Common stock placement extended to a total of $80 million as Sofinnova Ventures and Scopia Capital Management are added to Y-mAbs’ list of institutional shareholders
Read more

11-29-2017

YmAbs Raises $50 Million in Equity Financing

Y-mAbs Therapeutics, Inc. closes $50 million in a private placement led by HBM Healthcare Investments (HBM) and supported by current shareholders
Read more

10-24-2017

YmAbs Granted Rare Pediatric Disease Designation for hu3F8 Antibody

The FDA grants Y-mAbs Therapeutics, Inc. a Rare Pediatric Disease Designation for hu3F8 for the treatment of Neuroblastoma
Read more

07-05-2017

Burtomab Receives Breakthrough Therapy Designation for advanced form of pediatric cancer

Burtomab, a drug for metastatic neuroblastoma, has been granted Breakthrough Therapy Designation by the FDA for the treatment of pediatric patients with relapsed or refractory neuroblastoma with central nervous system or leptomeningeal metastasis
Read more

06-07-2017

YmAbs Announces Positive Topline Result in Pivotal Study of burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma

Positive burtomab data presented at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago
Read more

06-04-2017

YmAbs Announces Acceptance of Presentations of Burtomab Data at ASCO 2017 Annual Meeting

Pivotal efficacy data for 131I-burtomab treatments of Neuroblastoma CNS Metastases and DIPG has been accepted
Read more

05-09-2017